What Happened? Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after several negative developments weighed on the sector. Weakness ...

Supernus reported preliminary data in 2018 showing that the drug met the study’s goal. Last December, Supernus also announced positive results from a Phase 3 study testing its ADHD drug in adults.

Supernus Pharmaceuticals sued Indian generic drugmaker Zydus Cadila and its U.S. subsidiary in Manhattan federal court on Friday for allegedly infringing 10 patents with its proposed generic of ...

Supernus is pulling back after its strong post Q3, 2022 run. See why SUPN's Q4 earnings should be particularly interesting for shareholders.

Supernus Pharmaceuticals is up 1.8% during the same time and is heading into earnings with an average analyst price target of $38.80 (compared to the current share price of $32.84).

Supernus recognizes the potential size of the GOCOVRI market as potentially 400,000 US patients. For some reason it seems unable to imagine actually closing in on an appreciable percentage of ...

Supernus Pharmaceuticals (SUPN) reported $149.82 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 4.3%. EPS of $0.42 for the same period compares to ...

Deal adds Zurzuvae to Supernus' portfolio. Sage Therapeutics accepts $795M buyout from Supernus Pharmaceuticals, surpassing Biogen's offer. Washington Business Journal ...

Supernus Pharmaceuticals Inc said on Monday it would buy Adamas Pharmaceuticals Inc for about $400 million, to expand its roster of treatments for Parkinson's disease and reduce reliance on its ...